Inactive Instrument

Opko Health Stock price Nasdaq

Equities

Healthcare Facilities & Services

Sales 2024 * 772M Sales 2025 * 847M Capitalization 746M
Net income 2024 * -262M Net income 2025 * -187M EV / Sales 2024 * 0.97 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.88 x
P/E ratio 2024 *
-2.94 x
P/E ratio 2025 *
-4.21 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.99%
More Fundamentals * Assessed data
Dynamic Chart
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome CI
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing MT
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating MT
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
Opko Health Insider Bought Shares Worth $991,700, According to a Recent SEC Filing MT
HealthSnap, Inc. announced that it has received $24.999999 million in funding from a group of investors CI
OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board CI
NextPlat Preparing to Launch Opko Health Store on Alibaba's Tmall Global Platform MT
Opko Health Insider Bought Shares Worth $488,650, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $386,200, According to a Recent SEC Filing MT
More news
Managers TitleAgeSince
Chief Executive Officer 87 07-03-26
Director of Finance/CFO 46 07-02-28
President 71 22-05-08
Members of the board TitleAgeSince
Chief Executive Officer 87 07-03-26
Director/Board Member 77 20-12-17
Director/Board Member 68 07-12-31
More insiders
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock OPKO Health, Inc.
  4. Stock Opko Health - Nasdaq